5 Key Takeaways
-
1
Geographic atrophy (GA) is increasingly prevalent as the American population ages, affecting more patients daily.
-
2
There are currently two FDA-approved treatments for geographic atrophy, marking significant progress in the field.
-
3
Regeneron is developing a promising subcutaneous injection for GA, allowing patients to administer treatment at home.
-
4
Apellis is exploring a subcutaneous approach with pegcetacoplan to effectively reduce complement activity in GA.
-
5
Several gene therapy products are in clinical research, including one by Johnson & Johnson targeting MAC inhibition.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.